Navigation Links
PAREXEL International To Present At Goldman Sachs Emerging Growth Conference
Date:11/7/2013

BOSTON, Nov. 7, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Goldman Sachs Emerging Growth Conference on Thursday, November 14, 2013, in New York.  Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 11:20 a.m. ET.

A live webcast of the presentations will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until February 14, 2014.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 77 locations in 51 countries around the world, and has approximately 14,975 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL, Perceptive Informatics, LIQUENT, and HERON are registered trademarks of PAREXEL International Corporation or its affiliates.

Contact:
Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@parexel.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
11. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... genetically engineered to express human antibodies. The partnership will use GigaGen technology to ...
(Date:2/28/2017)... 2017  ITL Limited ( ASX:ITD ), an ... partner that provides innovative products and solutions to ... announces its rebrand to ITL Health Group (ITL). ... of the Company,s unified global rebranding plan and ... corporate website, ITLHealthGroup.com . ITL,s new brand ...
(Date:2/28/2017)... and NEW YORK , February 28, ... Application accepted by the FDA for avelumab  Prognosis ... has metastasized   EMD ... Germany , in the US and Canada ... Food and Drug Administration (FDA) has accepted for Priority Review ...
(Date:2/27/2017)... A Europe-wide survey of institutes conducted by the Basel Declaration ... treat them with due care. The survey polled a total of ... indicates that there is a strong commitment among animal researchers across ... of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? Refine: ...
Breaking Biology Technology:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global voice recognition biometrics market ... The report covers the present scenario and the ... To calculate the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):